Lexicon Genetics Inc. entered an agreement focused on neuroscience with Bristol-Myers Squibb Co. that provides an up-front payment of $36 million, with at least $30 million more in research funding during the next three years - and potentially another $50 million, if the deal is extended. (BioWorld Today) Read More
